The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 358:95-97 January 3, 2008 Number 1
NextNext

Home Blood-Pressure Monitoring in Patients Receiving Sunitinib

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
To the Editor: The use of sunitinib, an inhibitor of the split-kinase-domain family of receptor tyrosine kinases (including vascular endothelial growth factor receptor types 1 and 21), has been associated with a 15 to 25% incidence of hypertension in patients with advanced renal-cell carcinoma2,3; a similar incidence has been associated with other antiangiogenic drugs.3,4 We report on 14 consecutive patients with metastatic renal-cell carcinoma who were being treated with sunitinib and in whom home monitoring of blood pressure by teletransmission revealed a rapid, marked increase in blood pressure, an effect that was not detected by casual office measurement . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.